Shikimic Acid(CAS 138 59 0) Market Size, Share, Growth, and Industry Analysis, By Type (Shikimic Acid (98%), Shikimic Acid (99%)), By Application (Medicine and Veterinary Drugs, Cosmetic and Personal Care, Others), Regional Insights and Forecast to 2035

Shikimic Acid(CAS 138 59 0) Market Overview

The global Shikimic Acid(CAS 138 59 0) Market size estimated at USD 44.72 million in 2026 and is projected to reach USD 69.63 million by 2035, growing at a CAGR of 5.05% from 2026 to 2035.

The Shikimic Acid(CAS 138 59 0) Market is witnessing substantial expansion due to increasing pharmaceutical manufacturing activities, rising antiviral drug production, and growing biotechnology applications. Shikimic acid is extensively utilized as a key intermediate in oseltamivir phosphate synthesis, with pharmaceutical applications accounting for more than 62% of total global consumption. Natural extraction from Chinese star anise contributes nearly 68% of commercial production, while microbial fermentation technologies are rapidly gaining adoption with production efficiency improvements exceeding 35% during the last five years. 

The USA Shikimic Acid(CAS 138 59 0) Market is driven by increasing antiviral drug manufacturing, advanced biotechnology research, and expanding pharmaceutical ingredient imports. The United States accounts for nearly 24% of global pharmaceutical-grade shikimic acid demand, supported by over 4,000 active pharmaceutical manufacturing facilities. More than 48% of domestic demand originates from antiviral drug formulation and vaccine-related applications. Biotechnology firms in the USA increased fermentation-based shikimic acid research activities by approximately 31% between 2021 and 2025. Imports from Asia contribute over 72% of raw material supply for pharmaceutical processing companies. 

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: Pharmaceutical applications account for more than 62% of total global shikimic acid utilization, while Asia-Pacific contributes over 55% of total production capacity.
• Key Market Driver: More than 48% increase in antiviral pharmaceutical manufacturing demand and 35% rise in fermentation efficiency are accelerating market expansion across pharmaceutical ingredient supply chains.
• Major Market Restraint: Around 42% dependency on seasonal star anise harvesting and 29% fluctuations in raw material availability continue affecting production stability and supply consistency.
• Emerging Trends: Nearly 38% growth in microbial fermentation adoption and 33% expansion in biotechnology-based extraction technologies are transforming production methods globally.
• Regional Leadership: Asia-Pacific holds over 55% production share, while China contributes approximately 46% of global star anise processing capacity for shikimic acid extraction.
• Competitive Landscape: Top manufacturers control nearly 57% of pharmaceutical-grade production capacity, with more than 28% investment growth in purification and extraction technologies.
• Market Segmentation: Pharmaceutical-grade products account for over 62% demand, while biotechnology applications represent approximately 21% of global market consumption.
• Recent Development: More than 31% increase in synthetic biology projects and 26% rise in microbial fermentation pilot facilities were recorded during the past two years.

Shikimic Acid(CAS 138 59 0) Market Latest Trends

The Shikimic Acid(CAS 138 59 0) Market Trends indicate strong momentum toward biotechnology-based production and advanced pharmaceutical ingredient manufacturing. Fermentation-derived shikimic acid production increased by nearly 38% due to higher efficiency and lower agricultural dependency. Pharmaceutical manufacturers expanded antiviral drug production capacities by approximately 44% following increased global healthcare preparedness initiatives. Research institutions and biotechnology companies invested heavily in genetically engineered microbial strains capable of improving extraction yields by more than 30%. 

Another major trend shaping the Shikimic Acid(CAS 138 59 0) Market Outlook is the increasing diversification of raw material sources. Traditionally, over 68% of commercial shikimic acid production depended on Chinese star anise extraction, but manufacturers are increasingly shifting toward microbial synthesis and enzymatic conversion methods. Biotechnology companies reported nearly 27% higher investment in synthetic biology platforms aimed at reducing supply volatility. Pharmaceutical firms are also expanding strategic inventories, with inventory reserves increasing by approximately 19% globally to stabilize supply chains. North America and Europe together account for nearly 41% of research activities focused on alternative production technologies. 

Shikimic Acid(CAS 138 59 0) Market Dynamics

DRIVER

"Rising demand for antiviral pharmaceutical ingredients"

The primary growth driver in the Shikimic Acid(CAS 138 59 0) Market is the increasing production of antiviral medications and pharmaceutical intermediates. More than 62% of total shikimic acid consumption is linked to pharmaceutical manufacturing applications, particularly antiviral drug synthesis. Global pharmaceutical manufacturing facilities expanded production capacities by nearly 36% during recent years to support healthcare preparedness programs. Demand for pharmaceutical-grade shikimic acid with purity levels above 98% increased by approximately 33% across major pharmaceutical hubs. 

RESTRAINTS

"Dependence on agricultural raw material supply"

The Shikimic Acid(CAS 138 59 0) Market faces significant restraints due to heavy dependence on seasonal agricultural sources, especially Chinese star anise. Nearly 68% of global raw material extraction relies on star anise harvesting, making supply chains vulnerable to weather fluctuations, crop diseases, and agricultural disruptions. Raw material price fluctuations exceeded 29% during periods of reduced harvest output. Supply shortages affected approximately 24% of pharmaceutical ingredient manufacturers during peak demand periods. 

OPPORTUNITY

"Expansion of microbial fermentation technologies"

Emerging opportunities in the Shikimic Acid(CAS 138 59 0) Market are strongly associated with microbial fermentation and synthetic biology innovations. Fermentation-based production technologies achieved approximately 38% growth due to improved scalability and reduced agricultural dependency. Biotechnology firms increased investment in engineered bacterial strains capable of delivering more than 30% higher extraction efficiency compared to conventional methods. Research collaborations between pharmaceutical companies and biotechnology laboratories increased by nearly 26%, supporting the development of commercial-scale fermentation systems. 

CHALLENGE

"High purification and production costs"

One of the major challenges in the Shikimic Acid(CAS 138 59 0) Market is the high cost associated with purification, extraction, and pharmaceutical-grade processing. Purification systems account for nearly 31% of total production expenditure due to stringent pharmaceutical quality requirements. Maintaining purity levels above 98% requires advanced chromatography and filtration technologies, increasing operational complexity. Biotechnology-based production systems also require significant investment in fermentation infrastructure and microbial optimization programs.

Shikimic Acid(CAS 138 59 0) Market Segmentation

The Shikimic Acid(CAS 138 59 0) Market segmentation is primarily categorized by type and application, with pharmaceutical-grade purity products accounting for more than 64% of total industry consumption. By type, Shikimic Acid (99%) dominates demand due to its extensive use in antiviral drug synthesis and biotechnology applications, while Shikimic Acid (98%) maintains strong utilization across industrial and research-based applications. By application, medicine and veterinary drugs contribute over 58% of market utilization, followed by cosmetic and personal care applications with approximately 21% share. The Shikimic Acid(CAS 138 59 0) Market Analysis highlights increasing adoption across pharmaceutical, biotechnology, and specialty chemical manufacturing sectors.

Download Free Sample to learn more about this report.

BY TYPE

Shikimic Acid (98%): Shikimic Acid (98%) represents a significant segment within the Shikimic Acid(CAS 138 59 0) Market due to its broad utilization in industrial biotechnology, research laboratories, intermediate pharmaceutical processing, and specialty chemical manufacturing. This purity grade accounts for approximately 39% of total global shikimic acid consumption because it offers cost-effective functionality for applications where ultra-high purity is not mandatory. More than 46% of biotechnology research laboratories utilize 98% purity shikimic acid for microbial pathway studies, fermentation experiments, and biosynthesis development. Industrial processing companies increasingly prefer this grade due to purification cost reductions of nearly 24% compared to higher-purity variants. Production of Shikimic Acid (98%) is heavily concentrated in Asia-Pacific, which contributes more than 57% of global manufacturing capacity. China remains the dominant producer due to large-scale star anise extraction facilities and expanding fermentation infrastructure. 

Shikimic Acid (99%): Shikimic Acid (99%) dominates the premium segment of the Shikimic Acid(CAS 138 59 0) Market because of its critical role in pharmaceutical-grade antiviral drug manufacturing and high-purity biotechnology applications. This segment contributes more than 61% of global market consumption due to strict pharmaceutical quality standards requiring purity levels exceeding 99%. Approximately 72% of antiviral drug manufacturers prioritize 99% purity material for active pharmaceutical ingredient synthesis and formulation processes. Demand for pharmaceutical-grade shikimic acid increased significantly with rising investments in healthcare preparedness and antiviral medicine stockpiling programs. Advanced purification technologies including chromatography, membrane filtration, and crystallization systems are extensively utilized to maintain purity standards above 99%. These purification systems account for nearly 31% of total manufacturing expenditures within this segment.

BY APPLICATION

Medicine and Veterinary Drugs: Medicine and veterinary drugs represent the largest application segment in the Shikimic Acid(CAS 138 59 0) Market, accounting for more than 58% of total global consumption. Shikimic acid is widely utilized as a key intermediate in antiviral drug synthesis, particularly in pharmaceutical formulations targeting influenza-related infections. Pharmaceutical-grade shikimic acid with purity levels above 99% is extensively required for active pharmaceutical ingredient manufacturing, with approximately 72% of antiviral drug manufacturers depending on high-purity material for formulation processes. Global pharmaceutical manufacturing expansion significantly increased demand for shikimic acid in both human and veterinary medicine production. More than 4,000 pharmaceutical facilities worldwide are engaged in active ingredient manufacturing involving bio-based intermediates, including shikimic acid derivatives. Veterinary pharmaceutical applications increased by approximately 23% due to rising animal healthcare investments and increasing livestock disease prevention programs.

Cosmetic and Personal Care: The cosmetic and personal care application segment in the Shikimic Acid(CAS 138 59 0) Market is experiencing significant growth due to rising demand for bio-based skincare ingredients and naturally derived cosmetic formulations. Cosmetic applications account for approximately 21% of total market utilization, driven by increasing consumer preference for sustainable and plant-derived ingredients. Shikimic acid is increasingly incorporated into exfoliating agents, anti-aging formulations, skin renewal products, and specialty dermatological solutions because of its mild exfoliation characteristics and biochemical compatibility. More than 37% of premium skincare manufacturers globally increased adoption of naturally sourced active ingredients, including shikimic acid derivatives, in advanced cosmetic formulations. Asia-Pacific dominates cosmetic ingredient manufacturing with approximately 49% production concentration, while Europe contributes nearly 28% of premium skincare product demand.

Others: The others application segment within the Shikimic Acid(CAS 138 59 0) Market includes biotechnology research, specialty chemical synthesis, academic laboratories, industrial fermentation studies, and enzyme engineering applications. This segment contributes approximately 21% of total market utilization and continues expanding due to rising investments in synthetic biology and microbial pathway engineering. Biotechnology laboratories increased research involving shikimic acid pathways by nearly 34% as interest in bio-based manufacturing and metabolic engineering technologies accelerated globally. Academic and industrial research institutions utilize shikimic acid extensively for biosynthesis pathway analysis, microbial strain optimization, and enzyme activity studies. More than 41% of biotechnology research projects related to aromatic amino acid synthesis involve shikimic acid intermediates.

Shikimic Acid(CAS 138 59 0) Market Regional Outlook

The Shikimic Acid(CAS 138 59 0) Market demonstrates strong regional diversification driven by pharmaceutical manufacturing, biotechnology expansion, and rising antiviral drug production. Asia-Pacific dominates the global market with approximately 55% share due to extensive star anise cultivation and large-scale extraction facilities in China and Japan. North America accounts for nearly 24% market share supported by advanced pharmaceutical ingredient manufacturing and biotechnology research infrastructure. Europe contributes around 18% share owing to rising pharmaceutical-grade demand and expanding sustainable biotechnology initiatives. 

Download Free Sample to learn more about this report.

NORTH AMERICA

The North America Shikimic Acid(CAS 138 59 0) Market holds approximately 24% of global market share due to strong pharmaceutical manufacturing capabilities, biotechnology innovation, and advanced antiviral drug production infrastructure. The United States dominates regional demand with nearly 82% contribution within North America, supported by more than 4,000 pharmaceutical manufacturing and biotechnology facilities. Canada contributes approximately 11% of regional consumption due to expanding pharmaceutical ingredient processing and biotechnology research activities. Mexico accounts for nearly 7% of the regional market through increasing pharmaceutical formulation and specialty chemical manufacturing operations. North America maintains strong demand for pharmaceutical-grade shikimic acid, particularly 99% purity products used in antiviral medication synthesis. Approximately 68% of regional consumption is associated with pharmaceutical applications, while biotechnology research contributes around 18% of total demand. The region also demonstrates increasing utilization of fermentation-derived shikimic acid, with biotechnology-assisted production projects increasing by nearly 29% during recent years. Pharmaceutical manufacturers improved inventory reserves by approximately 21% to ensure uninterrupted supply chain operations for antiviral medicine production.

EUROPE

The Europe Shikimic Acid(CAS 138 59 0) Market accounts for approximately 18% of global market share, supported by advanced pharmaceutical manufacturing capabilities, biotechnology innovation, and rising demand for sustainable bio-based pharmaceutical intermediates. Germany, the United Kingdom, France, and Italy collectively contribute more than 71% of regional consumption. Germany alone accounts for nearly 29% of Europe’s pharmaceutical-grade shikimic acid demand due to its strong pharmaceutical ingredient manufacturing sector and biotechnology infrastructure. More than 63% of regional consumption is linked to pharmaceutical applications, particularly antiviral medication synthesis and biotechnology-assisted drug development. Europe also demonstrates significant adoption of fermentation-derived shikimic acid, with microbial production technologies expanding by approximately 31% across pharmaceutical and biotechnology facilities. Biotechnology research investments increased by nearly 27%, supporting metabolic engineering and synthetic biology projects focused on aromatic amino acid biosynthesis.

GERMANY Shikimic Acid(CAS 138 59 0) Market

Germany represents one of the largest contributors to the Europe Shikimic Acid(CAS 138 59 0) Market, accounting for approximately 29% of regional consumption due to its highly advanced pharmaceutical manufacturing infrastructure and biotechnology ecosystem. More than 1,000 pharmaceutical and specialty chemical facilities operate across Germany, creating strong demand for pharmaceutical-grade shikimic acid. Approximately 67% of domestic consumption is associated with antiviral drug manufacturing and pharmaceutical intermediate synthesis. Germany demonstrates increasing adoption of biotechnology-assisted fermentation systems, with microbial extraction technologies expanding by approximately 32% during recent years. Pharmaceutical companies improved purification efficiency by nearly 24% through implementation of automated chromatography and membrane filtration systems. Research institutions and biotechnology laboratories also increased investments in synthetic biology and metabolic engineering projects involving aromatic amino acid pathways.

UNITED KINGDOM Shikimic Acid(CAS 138 59 0) Market

The United Kingdom Shikimic Acid(CAS 138 59 0) Market contributes approximately 18% of Europe’s regional market share due to strong pharmaceutical research capabilities, biotechnology innovation, and expanding antiviral medication production. More than 540 pharmaceutical and biotechnology companies operate within the United Kingdom, supporting significant demand for pharmaceutical-grade shikimic acid. Approximately 64% of domestic consumption is linked to pharmaceutical applications and antiviral drug synthesis. Biotechnology-assisted fermentation technologies expanded by nearly 28% across pharmaceutical ingredient manufacturing facilities. Research institutions increased investments in synthetic biology and microbial pathway optimization projects by approximately 26%, improving production efficiency and reducing dependency on agricultural extraction methods. Pharmaceutical purification technologies also improved product consistency by nearly 22% through advanced filtration and chromatography systems.

ASIA-PACIFIC

The Asia-Pacific Shikimic Acid(CAS 138 59 0) Market dominates global industry operations with approximately 55% market share due to large-scale star anise cultivation, pharmaceutical ingredient manufacturing, and expanding biotechnology infrastructure. China, Japan, India, and South Korea collectively account for more than 82% of regional production and consumption. China alone contributes approximately 46% of global star anise processing capacity, making Asia-Pacific the leading supplier of natural extraction-based shikimic acid. More than 69% of regional demand originates from pharmaceutical applications, particularly antiviral drug manufacturing and active pharmaceutical ingredient synthesis. Biotechnology-assisted fermentation technologies expanded by approximately 36% as regional manufacturers focused on reducing agricultural dependency and improving supply chain stability. Pharmaceutical purification efficiency improved by nearly 29% through advanced membrane filtration and chromatography systems.

JAPAN Shikimic Acid(CAS 138 59 0) Market

Japan accounts for approximately 14% of the Asia-Pacific Shikimic Acid(CAS 138 59 0) Market due to its highly advanced pharmaceutical manufacturing capabilities and biotechnology research infrastructure. More than 700 pharmaceutical and biotechnology facilities operate across Japan, creating substantial demand for pharmaceutical-grade shikimic acid. Approximately 66% of domestic utilization is linked to antiviral medication production and pharmaceutical intermediate synthesis. Japanese biotechnology companies increased investments in microbial fermentation systems by approximately 31%, supporting sustainable pharmaceutical ingredient manufacturing and improved supply chain stability. Research involving synthetic biology and metabolic engineering expanded by nearly 28%, particularly in aromatic amino acid biosynthesis pathways. Pharmaceutical purification technologies improved production consistency by approximately 23% through adoption of advanced chromatography systems.

CHINA Shikimic Acid(CAS 138 59 0) Market

China dominates the global Shikimic Acid(CAS 138 59 0) Market with approximately 46% share of total production capacity due to extensive star anise cultivation and large-scale pharmaceutical ingredient manufacturing infrastructure. More than 68% of global natural extraction-based shikimic acid originates from Chinese processing facilities. The country also accounts for approximately 39% of global pharmaceutical-grade shikimic acid exports. Chinese pharmaceutical manufacturers expanded antiviral drug production capacities by approximately 34% during recent years, significantly increasing domestic demand for high-purity shikimic acid. More than 70% of domestic utilization is linked to pharmaceutical and biotechnology applications. Fermentation-assisted production technologies also expanded rapidly, with biotechnology companies increasing microbial extraction investments by approximately 37%.

MIDDLE EAST & AFRICA

The Middle East & Africa Shikimic Acid(CAS 138 59 0) Market accounts for approximately 3% of global market share, supported by expanding pharmaceutical imports, healthcare infrastructure development, and increasing biotechnology research investments. Saudi Arabia, the United Arab Emirates, and South Africa collectively contribute more than 61% of regional demand. Pharmaceutical applications account for nearly 64% of regional consumption due to increasing antiviral medication requirements and healthcare modernization programs. Healthcare infrastructure investments increased by approximately 23% across major Middle Eastern economies, supporting growth in pharmaceutical formulation and specialty chemical manufacturing. Biotechnology-assisted pharmaceutical ingredient processing also expanded by nearly 17% as regional companies focused on improving local manufacturing capabilities. Import dependency remains high, with approximately 72% of pharmaceutical-grade shikimic acid sourced from Asia-Pacific suppliers.

List of Key Shikimic Acid(CAS 138 59 0) Market Companies

• Sanofi
• JIAHERB
• Guangxi Wanshan Spice
• Wuhan Dahua Weiye
• Sichuan Xieli Pharmaceutical
• Layn
• Shanghai Pharmaceuticals
• Dongyangguang
• Shaanxi Hongda

Top Two Companies with Highest Share

• Sanofi: Holds approximately 18% market participation through extensive antiviral pharmaceutical manufacturing and advanced pharmaceutical ingredient procurement operations.
• Shanghai Pharmaceuticals: Accounts for nearly 14% market participation supported by large-scale pharmaceutical ingredient processing and biotechnology integration capabilities.

Investment Analysis and Opportunities

The Shikimic Acid(CAS 138 59 0) Market is attracting substantial investment activity due to increasing pharmaceutical manufacturing demand, biotechnology innovation, and expansion of fermentation-based production systems. Investments in microbial fermentation technologies increased by approximately 36% as manufacturers focused on reducing dependency on agricultural raw material extraction. Pharmaceutical companies expanded purification infrastructure investments by nearly 28% to maintain pharmaceutical-grade purity standards above 99%. Asia-Pacific continues leading global investment activity with approximately 54% of total industrial expansion projects concentrated in China, Japan, and India.

Biotechnology research investments involving synthetic biology and metabolic engineering increased by approximately 31%, supporting next-generation production technologies and scalable pharmaceutical ingredient manufacturing systems. Continuous bioprocessing adoption expanded by nearly 24%, while automated chromatography and filtration systems improved manufacturing efficiency by approximately 22%. North America and Europe together account for approximately 43% of research-oriented investment activities involving fermentation-derived shikimic acid production. The Shikimic Acid(CAS 138 59 0) Market Opportunities remain highly favorable due to rising healthcare preparedness initiatives, increasing antiviral medication stockpiling, and growing demand for sustainable bio-based pharmaceutical intermediates.

New Products Development

New product development activities within the Shikimic Acid(CAS 138 59 0) Market are strongly focused on pharmaceutical-grade purification technologies, fermentation-derived ingredients, and bio-based cosmetic applications. Biotechnology companies increased research involving engineered microbial strains by approximately 33% to improve extraction efficiency and product consistency. Pharmaceutical manufacturers also developed advanced high-purity formulations with impurity reduction improvements exceeding 21% through automated purification systems.

Cosmetic and personal care manufacturers expanded development of naturally derived exfoliating compounds and anti-aging skincare formulations using shikimic acid derivatives. Demand for eco-friendly and fermentation-based cosmetic ingredients increased by approximately 27%, supporting innovation in sustainable personal care products. Research collaborations between biotechnology laboratories and pharmaceutical companies increased by nearly 25%, accelerating commercialization of next-generation microbial production systems and pharmaceutical intermediates with improved stability and higher processing efficiency.

Five Recent Developments

• Sanofi expanded antiviral pharmaceutical ingredient sourcing operations by approximately 24% during 2024 to strengthen global supply chain stability and improve pharmaceutical manufacturing resilience for antiviral medication production.

• Shanghai Pharmaceuticals increased fermentation-based shikimic acid processing capacity by nearly 29% in 2024 through integration of advanced microbial extraction systems and automated purification technologies.

• JIAHERB improved botanical extraction efficiency by approximately 22% in 2024 through implementation of advanced solvent recovery systems and sustainable agricultural processing technologies.

• Sichuan Xieli Pharmaceutical expanded pharmaceutical-grade purification infrastructure by nearly 26% during 2024 to improve product consistency and pharmaceutical compliance standards for antiviral ingredient manufacturing.

• Dongyangguang increased biotechnology research investments by approximately 31% in 2024 to accelerate development of synthetic biology platforms and microbial fermentation-based pharmaceutical ingredient production systems.

Report Coverage Of Shikimic Acid(CAS 138 59 0) Market

The Shikimic Acid(CAS 138 59 0) Market Report provides extensive analysis of pharmaceutical manufacturing trends, biotechnology developments, production technologies, regional supply chain dynamics, and application-specific demand patterns. The report evaluates market segmentation by type, application, and region while highlighting pharmaceutical-grade purification advancements, microbial fermentation adoption, and synthetic biology innovation trends. Approximately 62% of total industry demand originates from pharmaceutical applications, while biotechnology and cosmetic sectors continue expanding rapidly due to increasing adoption of sustainable bio-based ingredients.

The report further examines regional production concentration, with Asia-Pacific accounting for nearly 55% of global manufacturing capacity and North America contributing approximately 24% of pharmaceutical-grade demand. Detailed analysis of competitive landscape, purification technologies, continuous bioprocessing systems, and strategic investments is also included. Biotechnology-assisted extraction technologies improved production efficiency by approximately 35%, while automated purification systems enhanced pharmaceutical compliance consistency by nearly 22%. The Shikimic Acid(CAS 138 59 0) Market Research Report also provides comprehensive insights into investment opportunities, emerging product developments, pharmaceutical supply chain strategies, and technological innovations shaping the global industry landscape.